Apollomics Inc. (APLM) stock

APLMNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as APLMW

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 24, 2026Score 0/30

$17.68+0.38 (+2.20%)

Close on Nov 13, 2026Market cap $38.83MP/E –Yield –

Apollomics r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $5.53M, down 77.5% from the year before. The highest annual figure on record is $35.57M in fiscal 2021.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$5.53M	-77.5%
FY2024	Dec 31, 2024	$24.57M	-28.2%
FY2023	Dec 31, 2023	$34.19M	-3.6%
FY2022	Dec 31, 2022	$35.46M	-0.3%
FY2021	Dec 31, 2021	$35.57M	+13.1%
FY2020	Dec 31, 2020	$31.44M	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is APLM.

Advertisement
300 × 250

See a number that looks wrong?